Zobrazeno 1 - 10
of 50 164
pro vyhledávání: ''
Autor:
Elizabeth Bancroft, Chee Goh, Elizabeth Page, Zsofia Kote-Jarai, Elena Castro, Christos Mikropoulos, Edward J. Saunders, Nandita M. deSouza, David E. Neal, Stephen Hazell, Antonis C. Antoniou, Natalie Taylor, Pardeep Kumar, Nigel Borley, Rosalind A. Eeles, Freddie C. Hamdy, Sibel Saya, Naomi Livni, Diana Keating, Tokhir Dadaev
Publikováno v:
The Oncologist
A better assessment of prostate cancer (PrCa) risk is needed to improve screening. The PROFILE pilot study explored the feasibility of single nucleotide polymorphism profiling in men with a family history (FH) of PrCa to investigate the probability o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::530db08f3b0071b7ef326b41d3c41f1a
https://ora.ox.ac.uk/objects/uuid:5985ee3f-ba82-44cd-9894-a0e866e55da9
https://ora.ox.ac.uk/objects/uuid:5985ee3f-ba82-44cd-9894-a0e866e55da9
Autor:
Thorsten Lehr, Hannah Britz, Clinton F. Stewart, Daniel Moj, Walter E. Haefeli, Gerlinde Egerer, Jürgen Burhenne
This study aimed at recommending pediatric dosages of the histone deacetylase (HDAC) inhibitor vorinostat and potentially more effective adult dosing regimens than the approved standard dosing regimen of 400 mg/day, using a comprehensive physiologica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b42701510c1983fe755fd57a7800a87
Autor:
Daniel Moj, Nicola Ammer, Babette Aicher, Jan-Georg Wojtyniak, Thorsten Lehr, Michael Teifel, Herbert Sindermann, Hannah Britz, Nina Hanke
Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study was to establish a physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c5e9a18956370d7aca5ee1061fd910
Publikováno v:
Clinical Lung Cancer. 23:e118-e130
To evaluate postoperative outcome and quality of life (QOL), comparing patients80 years old to patients ≥ 80.EORTC questionnaires, QLQ-C30 and QLQ-LC13 was used to assess QOL, in patients after surgery. Results were evaluated according to 3 age gro
Autor:
Xingpeng Han, Yin Li, Jian Hu, Yang Liu, Xiangning Fu, Xin Peng, Xiaofei Li, Tianyu He, Lunxu Liu, Heng Zhao, Yihe Wu, Jinming Xu, Deruo Liu, Lin Xu, Jinlin Cao
Publikováno v:
Clinical Lung Cancer. 23:170-176
Background Video-assisted thoracic surgery (VATS) has been widely used in the surgical treatment of thoracic diseases, and it suggested surgical and oncological advantages compared with open surgery. However, reports on the application of VATS in sur
Autor:
Li Zhu, Shuning Ding, Ou Huang, Weiguo Chen, Yafen Li, Weilin Chen, Xiaosong Chen, Jiayi Wu, Mengdi Chen, Caijin Lin, Deyue Liu, Kunwei Shen, Lisa Andriani, Jianrong He
Publikováno v:
Clinical Breast Cancer. 22:e147-e156
BACKGROUND In human epidermal growth factor receptor 2 (HER2)-positive breast cancer, emerging evidence imply that clinical behaviors differ according to hormone receptor (HR) status. However, there is no conclusion about the relevance between estrog
Autor:
C. Meyer, Y. Fouché, Emmanuel Chamorey, M. Dejode, C. Bailleux, J. Haudebourg, Renaud Schiappa, Y. Delpech, Emmanuel Barranger
Publikováno v:
Clinical Breast Cancer. 22:121-126
Background Delays in initiating adjuvant chemotherapy after breast cancer surgery seems to have an impact on patients’ risk of relapse and their survival rate. The aim of this retrospective study was to identify factors delaying initiation of adjuv
Autor:
Ashley J. Schlafstein, Karen D. Godette, Shannon Kahn, Mylin A. Torres, Subir Goyal, Jolinta Lin, Trevor J. Royce, Sagar A. Patel, Yuan Liu
Publikováno v:
Clinical Breast Cancer. 22:127-135
Neoadjuvant chemotherapy (NAC) is increasingly used for operable breast cancer (BC). Appropriate radiation therapy (RT) fields (ie, whole breast [WB] ± regional nodal irradiation [RNI]) in patients who were clinically node positive (cN1) but convert
Autor:
Louis B. Nabors, David A. Reardon, John Simes, Lisa Roberts-Rapp, Ho-Jin Lee, Nicholas Butowski, Tobias Walbert, Andrew B. Lassman, Helen Wheeler, Priya Kumthekar, Andrew M. Scott, Peter Ansell, Tom Mikkelsen, Marta Penas-Prado, Kyriakos P. Papadopoulos, Martin J. van den Bent, Earle Bain, Zarnie Lwin, Erica Gomez, David Maag, Ryan Merrell, Hui K Gan, Hao Xiong, Kyle D. Holen
Publikováno v:
Cancer Chemotherapy & Pharmacology, 80(6), 1209-1217. Springer-Verlag
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, is an antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff65c6833473b7cdb380bda35882ca5
Autor:
Bhumsuk Keam, Keon Uk Park, Hye Ryun Kim, Keun-Wook Lee, Sung-Bae Kim, Seong Hoon Shin, Jin-Hyuk Choi, Eun Joo Kang, Yun-Gyoo Lee, Hyo Jung Kim, Min Kyoung Kim, Hwan Jung Yun, Kyoung Eun Lee, Jin-Soo Kim, Hee Kyung Ahn
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose Certain patient subgroups who do not respond to induction chemotherapy (IC) show inherent chemoresistance in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This study aimed to assess the prognostic value of IC, and role of